August 7, 2026
Betting on hope? The comments explode
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
People are horrified as drug-trial betting sparks "evil casino" backlash
TLDR: Kalshi and Polymarket are taking bets on medical trial results, and critics say that turns patients’ suffering into a gambling event. Online, people are split between calling it monstrous and saying Wall Street already does the same thing with drug stocks — just with a fancier label.
The internet absolutely did not keep calm when news broke that Kalshi and Polymarket are letting people bet on whether medical trials succeed and whether the U.S. Food and Drug Administration, the government agency that approves medicines, gives new drugs a thumbs-up. The article’s emotional center is a Boston dad whose cancer-stricken son is in a clinical trial right now — and commenters seized on that human reality fast. For many, this wasn’t just “a market.” It was people turning life-and-death treatment into a game board.
The harshest reaction came from users calling these platforms “insider trading casinos” and accusing them of being “brazenly evil.” That set the tone: disgust, disbelief, and a lot of “how is this even allowed?” energy. But then came the fight. A rival camp argued this is basically no different from Wall Street already betting on drug companies through stocks, options, and short selling. In other words: if people already profit when trials flop, why is this suddenly the moral red line?
That clash made the comments spicy. One side said betting could even help point money toward promising treatments. The other side said that logic is ghoulish when real patients are attached — and worried it could tempt insiders to tamper with trials. There weren’t many jokes because the topic is dark, but the phrase “insider trading casinos” landed like a savage meme and instantly became the thread’s unofficial slogan.
Key Points
- •The article reports that Kalshi and Polymarket have begun offering bets on clinical trial outcomes and on FDA approval decisions for new drugs.
- •Joshua Pederson, whose son is enrolled in a cancer clinical trial, says betting on trial failure ignores the human consequences for patients and families.
- •Kalshi says these markets can provide useful information about likely drug approvals and trial results, potentially helping investors allocate funding.
- •Kalshi spokesman Jack Such compares these bets with stock market short selling, arguing that profit incentives tied to trial failure already exist in larger financial markets.
- •Researchers including David Tsai and Nicholas Zaorsky warn that such betting could undermine trust in biotechnology and create incentives to tamper with trial conditions or results.